losartan-potassium has been researched along with 1-3-dipropyl-8-cyclopentylxanthine* in 2 studies
2 other study(ies) available for losartan-potassium and 1-3-dipropyl-8-cyclopentylxanthine
Article | Year |
---|---|
Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death.
Fractalkine/CX3CL1 is a neuron-associated chemokine, which modulates microglia-induced neurotoxicity activating the specific and unique receptor CX3CR1. CX3CL1/CX3CR1 interaction modulates the release of cytokines from microglia, reducing the level of tumor necrosis factor-alpha, interleukin-1-beta, and nitric oxide and induces the production of neurotrophic substances, both in vivo and in vitro. We have recently shown that blocking adenosine A(1) receptors (A(1)R) with the specific antagonist 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) abolishes CX3CL1-mediated rescue of neuronal excitotoxic death and that CX3CL1 induces the release of adenosine from microglia. In this study, we show that the presence of extracellular adenosine is mandatory for the neurotrophic effect of CX3CL1 as reducing adenosine levels in hippocampal cultures, by adenosine deaminase treatment, strongly impairs CX3CL1-mediated neuroprotection. Furthermore, we confirm the predominant role of microglia in mediating the neuronal effects of CX3CL1, because the selective depletion of microglia from hippocampal cultures treated with clodronate-filled liposomes causes the complete loss of effect of CX3CL1. We also show that hippocampal neurons obtained from A(1)R(-/-) mice are not protected by CX3CL1 whereas A(2A)R(-/-) neurons are. The requirement of functional A(1)R for neuroprotection is not unique for CX3CL1 as A(1)R(-/-) hippocampal neurons are not rescued from Glu-induced cell death by other neurotrophins such as brain-derived neurotrophic factor and erythropoietin, which are fully active on wt neurons. Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine Deaminase; Adenosine Diphosphate; Animals; Animals, Newborn; Brain-Derived Neurotrophic Factor; Cell Death; Cell Movement; Clodronic Acid; CX3C Chemokine Receptor 1; Erythropoietin; Glutamic Acid; Green Fluorescent Proteins; Hippocampus; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Neurons; Organ Culture Techniques; Rats; Receptor, Adenosine A1; Receptors, Adenosine A2; Receptors, Chemokine; Xanthines | 2010 |
Evidence against a major role of adenosine in oxygen-dependent regulation of erythropoietin in rats.
This in vivo study investigated whether adenosine (ADO) plays a role in oxygen-dependent production of erythropoietin (EPO). Exposure of rats to 0.075% carbon monoxide (CO) for four hours was used as a stimulus for EPO production. To inhibit potential effects of ADO, rats were treated with the non-specific ADO antagonist theophylline, the selective ADO A1 receptor blockers DPCPX and KW-3902, the selective ADO A2 receptor blocker DMPX, and AOPCP, an inhibitor of 5'-ectonucleotidase, an ADO generating enzyme that is expressed on the surface of EPO producing cells. To stimulate ADO receptor activity, animals were treated with the selective ADO A1 and A2 receptor agonists CHA and CGS 21680, the ADO reuptake inhibitors dipyridamole and soluflazine and the ADO desaminase inhibitor EHNA. At doses known to interfere with ADO signal transmission in vivo, none of these substances either influenced EPO serum levels in normoxic rats or affected the approximately 30-fold rise in EPO serum levels and the increase in renal EPO mRNA after exposure to carbon monoxide. Continuous administration of theophylline to normoxic rats for seven days did not alter hematocrit, hemoglobin or EPO serum levels. Taken together, these experiments do not support the hypothesis that ADO plays an important role in the regulation of EPO production. Topics: Adenine; Adenosine; Adenosine Diphosphate; Animals; Antihypertensive Agents; Carbon Monoxide; Dipyridamole; Diuretics; Drug Synergism; Enzyme Inhibitors; Erythropoietin; Gene Expression; Hypoxia; Kidney; Male; Oxygen; Phenethylamines; Phosphodiesterase Inhibitors; Piperazines; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Rats, Wistar; Receptors, Purinergic P1; RNA, Messenger; Theophylline; Vasodilator Agents; Xanthines | 1997 |